+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Uterine Fibroid Treatment Devices Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • May 2024
  • Region: Global
  • Expert Market Research
  • ID: 5780690
The global uterine fibroid treatment devices market size was valued at USD 6.2 billion in 2023. It is expected to grow at a CAGR of 9.66% during the forecast period of 2024-2032, driven by rising shift towards minimally invasive procedures across the globe. It is expected to attain a value of USD 14.2 billion by 2032.

Global Uterine Fibroid Treatment Devices Market Analysis

The global uterine fibroid treatment devices market is a critical segment within the broader women's health and medical devices industries, focused on addressing uterine fibroids, non-cancerous growths of the uterus that often appear during childbearing years. This market analysis provides an overview of the current landscape, driving factors, challenges, and future prospects of the global uterine fibroid treatment devices market.

Market Overview

Uterine fibroids are among the most common benign tumors in women, with a significant impact on health, fertility, and quality of life. The demand for effective and minimally invasive treatment options is driving the growth of the uterine fibroid treatment devices market. This market encompasses a range of devices and technologies, including endometrial ablation devices, uterine fibroid embolization (UFE) materials, laparoscopic power morcellators, hysteroscopes, and radiofrequency ablation devices.

Key Drivers

Several factors contribute to the growth of the uterine fibroid treatment devices market:

  • Increasing Prevalence of Uterine Fibroids: A growing number of women are being diagnosed with uterine fibroids, attributed to rising awareness, better diagnostic techniques, and delayed childbearing.
  • Advancements in Treatment Technologies: Innovation in minimally invasive technologies offers effective treatment options with reduced recovery times and fewer complications, making them more appealing to patients and healthcare providers.
  • Growing Preference for Minimally Invasive Procedures: There is a clear trend towards minimally invasive surgeries over traditional open surgeries due to their benefits of smaller incisions, less pain, and quicker recovery.
  • Rising Healthcare Expenditure: Increased healthcare spending globally is enabling better access to treatments, including advanced procedures for uterine fibroid management.


Despite significant growth, the uterine fibroid treatment devices market faces challenges:

  • Lack of Awareness and Underdiagnosis: In many regions, especially in low- and middle-income countries, a lack of awareness and limited access to healthcare facilities lead to underdiagnosis and undertreatment of uterine fibroids.
  • Concerns Over Device Safety: Certain devices, such as power morcellators, have faced scrutiny over safety concerns, impacting their adoption rates.
  • Cost and Reimbursement Issues: High costs associated with advanced treatment options and inconsistent reimbursement policies can limit patient access to these treatments.

Global Uterine Fibroid Treatment Devices Market Trends

The global uterine fibroid treatment devices market is witnessing significant transformations, driven by technological advancements, changing healthcare policies, and evolving patient preferences. Uterine fibroids, benign tumors that develop within the muscle tissue of the uterus, are a common health concern among women, particularly during their reproductive years. While they often remain asymptomatic, they can lead to complications such as heavy menstrual bleeding, pain, and fertility issues. The demand for minimally invasive and effective treatments has led to the development and adoption of innovative devices, shaping the market trends in this sector. Here are the key trends currently influencing the global uterine fibroid treatment devices market:

1. Shift Towards Minimally Invasive Procedures

There's a growing preference for minimally invasive treatments over traditional surgical methods like hysterectomy. Techniques such as uterine artery embolization (UAE), radiofrequency ablation, and magnetic resonance-guided focused ultrasound (MRgFUS) are gaining popularity. These methods offer benefits like shorter recovery times, less pain, and reduced risk of complications, aligning with patients' desires for treatments that have minimal impact on their daily lives and fertility.

2. Advancements in Imaging Technologies

Improvements in imaging technologies are enhancing the diagnosis and treatment of uterine fibroids. High-resolution ultrasound and magnetic resonance imaging (MRI) enable precise localization and characterization of fibroids, which is crucial for the success of minimally invasive treatments. These advancements not only improve the effectiveness of treatments but also help in customizing treatment plans to individual patient needs.

3. Increased Focus on Outpatient Care

There's a trend towards providing uterine fibroid treatments in outpatient settings, driven by the development of less invasive treatment options and the desire to reduce healthcare costs. This shift is facilitated by the shorter recovery times associated with these treatments, allowing patients to return home the same day. Outpatient care is becoming more appealing to both patients and healthcare providers, as it offers a convenient and cost-effective alternative to inpatient surgery.

4. Rising Demand for Non-surgical Options

The market is experiencing an increased demand for non-surgical treatment options, such as pharmacological therapies that target the hormonal pathways involved in fibroid growth. While these options may not replace the need for surgical intervention in all cases, they provide alternatives for managing symptoms and potentially reducing fibroid size, catering to patients seeking non-invasive approaches.

5. Growing Awareness and Education

Increased awareness and education about uterine fibroids and their treatment options are empowering women to seek care. Healthcare campaigns and patient advocacy groups are playing a significant role in disseminating information about fibroids, debunking myths, and encouraging women to discuss symptoms and treatment preferences with their healthcare providers. This trend is contributing to the early diagnosis and treatment of fibroids, potentially improving outcomes for many women.

6. Expansion in Emerging Markets

The uterine fibroid treatment devices market is expanding in emerging markets, driven by rising healthcare infrastructure, increasing access to healthcare services, and growing awareness of fibroid treatments. Countries in regions such as Asia-Pacific, Latin America, and Africa are witnessing increased investments in healthcare, providing opportunities for market growth in uterine fibroid treatments.

The global uterine fibroid treatment devices market is evolving rapidly, with a clear trend towards minimally invasive, patient-friendly treatments. Advances in technology, coupled with changing patient preferences and healthcare practices, are shaping the future of fibroid treatment. As the market continues to grow, stakeholders must stay abreast of these trends to meet the changing needs of patients and capitalize on emerging opportunities in both developed and developing regions.

Global Uterine Fibroid Treatment Devices Market Segmentation

Market Breakup by Technology

  • Surgical Techniques
  • Hysterectomy
  • Myomectomy
  • Laparoscopic Techniques
  • Laparoscopic Myomectomy
  • Myolysis
  • Ablation Techniques
  • Microwave Ablation
  • Hydrothermal Ablation
  • Cryoblation
  • Ultrasound Ablation
  • High- Intensity Focused Ultrasound (HIFU)
  • MRI-Guided Focused Ultrasound (MRGFUS)
  • Other Ablation Techniques
  • Embolization Techniques
The global uterine fibroid treatment devices market is segmented by technology into surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques, including hysterectomy and myomectomy, are traditional methods but are gradually being replaced by minimally invasive procedures. Laparoscopic techniques like laparoscopic myomectomy and myolysis offer shorter recovery times and less scarring. Ablation techniques, such as microwave, hydrothermal, cryoablation, ultrasound ablation, HIFU, and MRGFUS, are gaining popularity due to their precision and reduced side effects. Embolization techniques are also emerging as a viable option. The market is driven by the rising prevalence of uterine fibroids, advancements in medical technology, and the growing preference for minimally invasive procedures. Minimally invasive techniques, particularly ablation and embolization, are expected to drive market growth during the forecast period due to their effectiveness and patient-friendly nature.

Market Breakup by Mode of Treatment

  • Invasive Treatment
  • Minimally Invasive Treatment Oncology
  • Non-Invasive Treatment
The global uterine fibroid treatment devices market is also segmented by mode of treatment into invasive treatment, minimally invasive treatment, and non-invasive treatment. Invasive treatments typically involve traditional surgical procedures such as hysterectomy and myomectomy, which require longer recovery times and are associated with higher risks. Minimally invasive treatments, on the other hand, include laparoscopic techniques, ablation methods, and embolization techniques, which are favored for their reduced recovery times, lower risks of complications, and less scarring. Non-invasive treatments, such as high-intensity focused ultrasound (HIFU) and MRI-guided focused ultrasound (MRgFUS), are gaining traction due to their ability to treat fibroids without incisions or anesthesia. The market is expected to be driven by the increasing adoption of minimally invasive and non-invasive treatments, as patients seek safer and more convenient alternatives to traditional surgery.

Market Breakup by End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others
The global uterine fibroid treatment devices market is segmented by end users into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are the primary end users, as they are equipped with the necessary infrastructure and skilled personnel to perform a wide range of uterine fibroid treatments, from invasive surgeries to minimally invasive and non-invasive procedures. Clinics are also significant end users, providing specialized care for patients with uterine fibroids. Ambulatory surgical centers are growing in popularity due to their efficiency in performing outpatient procedures, including minimally invasive treatments. The "others" category includes settings such as research institutions and home care services. The market is expected to grow as advancements in treatment technologies increase the demand for uterine fibroid treatment devices across all end-user segments.

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
The global uterine fibroid treatment devices market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Key market drivers include rising awareness and diagnosis rates of uterine fibroids, advancements in treatment technologies, and increasing preference for minimally invasive surgical procedures. The Asia Pacific region is anticipated to witness significant future growth due to its expanding healthcare infrastructure, growing female population, and rising healthcare expenditure. This segment's growth is poised to substantially contribute to the overall market expansion during the forecast period, driven by demographic shifts, technological innovations, and improving healthcare access across these diverse regions.

Global Uterine Fibroid Treatment Devices Market Competitive Landscape

The competitive landscape of the Global Uterine Fibroid Treatment Devices Market is characterized by the presence of leading players including Advanced Surgical Concepts, Boston Scientific Corporation, CONMED Corporation, CooperSurgical Inc., Hologic, Inc., Medtronic, Olympus Corporation, Pentax Medical, Stryker, Minerva Surgical, Inc., Lumenis Be Ltd., Insightec, Gynesonics, Merit Medical Systems, and Chongqing Haifu Medical Technology Co., Ltd.

These key players are actively engaged in various market activities such as mergers and acquisitions (M&A), research and development (R&D) initiatives, product launches, and collaborations to enhance their market position and respond to the growing demand for innovative and effective uterine fibroid treatment solutions. Their efforts are aimed at expanding their product portfolios, entering new markets, and establishing strategic partnerships, thereby driving competitive dynamics and innovation within the market.

Key Questions Answered in This Report

  • What is the current and future performance of the global uterine fibroid treatment devices market?
  • What are the key drivers for the growth of the market for uterine fibroid treatment?
  • What are the challenges and future prospects for the uterine fibroid treatment devices market?
  • How is the growing preference for minimally invasive treatments is expected to influence the market?
  • How is the market segmented on the basis of technology?
  • What are the market segmentation by treatment in the market?
  • What are the common risks and recovery times associated with invasive treatments for uterine fibroids?
  • Which healthcare facilities are the primary end users for uterine fibroid treatments and why?
  • Who are the key players in the global uterine fibroid treatment devices market?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global uterine fibroid treatment devices market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global uterine fibroid treatment devices market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the uterine fibroid treatment devices industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology3 Executive Summary
4 Global Uterine Fibroid Treatment Devices Market
4.1 Global Uterine Fibroid Treatment Devices Market Overview
4.2 Global Uterine Fibroid Treatment Devices Market Analysis
4.2.1 Market Overview Global Uterine Fibroid Treatment Devices Market Historical Value (2017-2023) Global Uterine Fibroid Treatment Devices Market Forecast Value (2024-2032)
4.3 Global Uterine Fibroid Treatment Devices Market by Mode of Treatment
4.3.1 Market Overview Invasive System Non-Invasive System Minimally Invasive System
4.4 Global Uterine Fibroid Treatment Devices Market by Techniques
4.4.1 Market Overview Surgical Techniques Hysterectomy Myomectomy Laparoscopic Techniques Laparoscopic Myolosis Ablation Techniques Microwave Ablation Cryoablation Ultrasound Ablation Embolization Techniques Others
4.5 Global Uterine Fibroid Treatment Devices Market by End-User
4.5.1 Market Overview Hospitals Dialysis Centres Others
4.6 Global Uterine Fibroid Treatment Devices Market by Region
4.6.1 Market Overview North America Europe Asia Pacific Latin America Middle East and Africa
4.6.2 North America Historical Trend (2017-2023) Forecast Trend (2024-2032) Break Up by Country United States of America Canada
4.6.3 Europe Historical Trend (2017-2023) Forecast Trend (2024-2032) Break Up by Country United Kingdom Germany France Italy Others
4.6.4 Asia Pacific Historical Trend (2017-2023) Forecast Trend (2024-2032) Break Up by Country China Japan India ASEAN Australia Others
4.6.5 Latin America Historical Trend (2017-2023) Forecast Trend (2024-2032) Break Up by Country Brazil Argentina Mexico Others
4.6.6 Middle East and Africa Historical Trend (2017-2023) Forecast Trend (2024-2032) Break Up by Country Saudi Arabia United Arab Emirates Nigeria South Africa Others
5 Trade Data Analysis by HS Code- XXXX
6 Regulations and Clinical Assessment
6.1 Regulatory Capabilities
6.2 Patent Landscape
6.3 Clinical Trials
7 Global Uterine Fibroid Treatment Devices Industry Dynamics
7.1 Industry Drivers and Constraints
7.2 Porters
7.3 SWOT Analysis
7.4 Key Demand Indicator Analysis
7.5 Key Price Indicator Analysis
7.6 Industry Events, Initiatives, and Trends
7.7 Value Chain
8 Global Uterine Fibroid Treatment Devices Distribution Model (Additional Insights)
8.1 Overview
8.2 Potential Distributor
8.3 Key Parameters for Distribution Partner Assessment
9 Supplier Landscape
9.1 Medtronic
9.1.1 Company Overview
9.1.2 Product Portfolio
9.1.3 Demographic Reach and Achievements
9.1.4 Mergers and Acquisitions
9.1.5 Certifications
9.2 Boston Scientific Corporation
9.2.1 Company Overview
9.2.2 Product Portfolio
9.2.3 Demographic Reach and Achievements
9.2.4 Mergers and Acquisitions
9.2.5 Certifications
9.3 Cooper Surgical Inc.
9.3.1 Company Overview
9.3.2 Product Portfolio
9.3.3 Demographic Reach and Achievements
9.3.4 Mergers and Acquisitions
9.3.5 Certifications
9.4 Stryker Corporation
9.4.1 Company Overview
9.4.2 Product Portfolio
9.4.3 Demographic Reach and Achievements
9.4.4 Mergers and Acquisitions
9.4.5 Certifications
9.5 Minerva Surgical, Inc
9.5.1 Company Overview
9.5.2 Product Portfolio
9.5.3 Demographic Reach and Achievements
9.5.4 Mergers and Acquisitions
9.5.5 Certifications
9.6 AbbVie Inc.
9.6.1 Company Overview
9.6.2 Product Portfolio
9.6.3 Demographic Reach and Achievements
9.6.4 Mergers and Acquisitions
9.6.5 Certifications
9.7 Ethicon, Inc.
9.7.1 Company Overview
9.7.2 Product Portfolio
9.7.3 Demographic Reach and Achievements
9.7.4 Mergers and Acquisitions
9.7.5 Certifications
9.8 Lumenis Ltd
9.8.1 Company Overview
9.8.2 Product Portfolio
9.8.3 Demographic Reach and Achievements
9.8.4 Mergers and Acquisitions
9.8.5 Certifications
9.9 Smith & Nephew PLC
9.9.1 Company Overview
9.9.2 Product Portfolio
9.9.3 Demographic Reach and Achievements
9.9.4 Mergers and Acquisitions
9.9.5 Certifications
9.10 Merit Medical Systems, Inc.
9.10.1 Company Overview
9.10.2 Product Portfolio
9.10.3 Demographic Reach and Achievements
9.10.4 Mergers and Acquisitions
9.10.5 Certifications
9.11 Hologic, Inc.
9.11.1 Company Overview
9.11.2 Product Portfolio
9.11.3 Demographic Reach and Achievements
9.11.4 Mergers and Acquisitions
9.11.5 Certifications
9.12 ConMed Corporation
9.12.1 Company Overview
9.12.2 Product Portfolio
9.12.3 Demographic Reach and Achievements
9.12.4 Mergers and Acquisitions
9.12.5 Certifications
9.13 Gynesonics, Inc
9.13.1 Company Overview
9.13.2 Product Portfolio
9.13.3 Demographic Reach and Achievements
9.13.4 Mergers and Acquisitions
9.13.5 Certifications
10 Recommendations and Discussion
11 Pricing Models and Strategies (Additional Insight)
11.1 Overview
11.2 Cost Model
11.2.1 Manufacturing Cost Analysis
11.2.2 Procurement Cost Analysis
11.2.3 Clinical Trial Cost Factors
11.3 Pricing Strategies
11.3.1 Competitor pricing Analysis
11.3.2 Key Assessment of Product Attributes
11.3.3 Pricing Benchmark

Companies Mentioned

  • Medtronic
  • Boston Scientific Corporation
  • Cooper Surgical Inc.
  • Stryker Corporation
  • Minerva Surgical, Inc
  • AbbVie Inc.
  • Ethicon, Inc.
  • Lumenis Ltd
  • Smith & Nephew PLC
  • Merit Medical Systems, Inc.
  • Hologic, Inc.
  • ConMed Corporation
  • Gynesonics, Inc



Table Information